104 related articles for article (PubMed ID: 29729983)
21. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy.
Bishop AJ; Ensor J; Moulder SL; Shaitelman SF; Edson MA; Whitman GJ; Bishnoi S; Hoffman KE; Stauder MC; Valero V; Buchholz TA; Ueno NT; Babiera G; Woodward WA
Cancer; 2015 Dec; 121(24):4324-32. PubMed ID: 26348887
[TBL] [Abstract][Full Text] [Related]
22. [Treatment results of Hodgkin's lymphoma].
Aleknavicius E; Valuckas KP; Aleknaviciene B; Norkiene L; Smailyte G
Medicina (Kaunas); 2009; 45(8):615-23. PubMed ID: 19773620
[TBL] [Abstract][Full Text] [Related]
23. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era.
Evens AM; Helenowski I; Ramsdale E; Nabhan C; Karmali R; Hanson B; Parsons B; Smith S; Larsen A; McKoy JM; Jovanovic B; Gregory S; Gordon LI; Smith SM
Blood; 2012 Jan; 119(3):692-5. PubMed ID: 22117038
[TBL] [Abstract][Full Text] [Related]
24. [Clinicopathologic characteristics and prognosis of neoplastic cell-rich mixed cellularity classic Hodgkin lymphoma].
Hou WH; Wei P; Xie JL; Zheng YY; Zhou XG
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):708-713. PubMed ID: 29050074
[No Abstract] [Full Text] [Related]
25. Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network.
Farrell K; McKay P; Leach M
Leuk Lymphoma; 2011 Oct; 52(10):1920-8. PubMed ID: 21663507
[TBL] [Abstract][Full Text] [Related]
26. Impact of chest wall and lung invasion on outcome of stage I-II Hodgkin's lymphoma after combined modality therapy.
Hodgson DC; Tsang RW; Pintilie M; Sun A; Wells W; Crump M; Gospodarowicz MK
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1374-81. PubMed ID: 14630276
[TBL] [Abstract][Full Text] [Related]
27. How do organ-specific metastases affect prognosis and surgical treatment for patients with metastatic upper tract urothelial carcinoma: first evidence from population based data.
Dong F; Fu H; Shi X; Shen Y; Xu T; Gao F; Wang X; Zhong S; Ding Q; Shen Z; Chen S
Clin Exp Metastasis; 2017 Dec; 34(8):467-477. PubMed ID: 29500709
[TBL] [Abstract][Full Text] [Related]
28. Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy.
Gobbi PG; Bassi E; Bergonzi M; Merli F; Coriani C; Iannitto E; Luminari S; Polimeno G; Federico M
Hematol Oncol; 2012 Dec; 30(4):194-9. PubMed ID: 22271092
[TBL] [Abstract][Full Text] [Related]
29. [A analysis of the outcome and prognostic factors in 415 patients with Hodgkin lymphoma].
Tao Y; Kang S; Zhou L; Shi Y; Li Y; Sun Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):466-71. PubMed ID: 26463153
[TBL] [Abstract][Full Text] [Related]
30. Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation.
Gunther JR; Fanale MA; Reddy JP; Akhtari M; Smith GL; Pinnix CC; Milgrom SA; Yehia ZA; Allen PK; Osborne EM; Mawlawi O; Dabaja BS
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):110-8. PubMed ID: 27325479
[TBL] [Abstract][Full Text] [Related]
31. Radiation therapy for early stage unfavorable Hodgkin lymphoma: is dose reduction feasible?
Laskar S; Kumar DP; Khanna N; Menon H; Sengar M; Arora B; Gujral S; Shet T; Sridhar E; Rangarajan V; Muckaden MA; Nair R; Banavali S
Leuk Lymphoma; 2014 Oct; 55(10):2356-61. PubMed ID: 24354681
[TBL] [Abstract][Full Text] [Related]
32. Pediatric pulmonary Hodgkin lymphoma: analysis of 10 years data from a single center.
Urasinski T; Kamienska E; Gawlikowska-Sroka A; Ociepa T; Maloney E; Chosia K; Walecka A
Eur J Med Res; 2010 Nov; 15 Suppl 2(Suppl 2):206-10. PubMed ID: 21147653
[TBL] [Abstract][Full Text] [Related]
33. Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features: A phase II Cancer and Leukemia Group B Study (9051).
Wasserman TH; Petroni GR; Millard FE; Chung CT; Barcos M; Johnson JL; Canellos GP; Peterson BA
Cancer; 1999 Oct; 86(8):1590-5. PubMed ID: 10526290
[TBL] [Abstract][Full Text] [Related]
34. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
35. Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients-An analysis from the Brazilian Hodgkin Lymphoma Registry.
Biasoli I; Castro N; Delamain M; Silveira T; Farley J; Pinto Simões B; Solza C; Praxedes M; Baiocchi O; Gaiolla R; Franceschi F; Bonamin Sola C; Boquimpani C; Clementino N; Fleury Perini G; Pagnano K; Steffenello G; Tabacof J; de Freitas Colli G; Soares A; de Souza C; Chiattone CS; Raggio Luiz R; Milito C; Morais JC; Spector N
Int J Cancer; 2018 Mar; 142(5):883-890. PubMed ID: 29023692
[TBL] [Abstract][Full Text] [Related]
36. Impact of multimodal treatment on prognosis for patients with metastatic upper urinary tract urothelial cancer: Subanalysis of the multi-institutional nationwide case series study of the Japanese Urological Association.
Inokuchi J; Naito S; Fujimoto H; Hara T; Sakura M; Nishiyama H; Miyazaki J; Kikuchi E; Hinotsu S; Koie T; Ohyama C;
Int J Urol; 2016 Mar; 23(3):224-30. PubMed ID: 26659912
[TBL] [Abstract][Full Text] [Related]
37. No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.
Jakobsen LH; Hutchings M; de Nully Brown P; Linderoth J; Mylam KJ; Molin D; Johnsen HE; Bøgsted M; Jerkeman M; El-Galaly TC
Br J Haematol; 2016 Apr; 173(2):236-44. PubMed ID: 26846879
[TBL] [Abstract][Full Text] [Related]
38. Hodgkin lymphoma in Tyrol-a population-based study.
Fong D; Steurer M; Greil R; Gunsilius E; Spizzo G; Gastl G; Tzankov A
Ann Hematol; 2009 May; 88(5):449-56. PubMed ID: 18846373
[TBL] [Abstract][Full Text] [Related]
39. Young adults diagnosed with Hodgkin lymphoma are at risk of relapsing late: a comprehensive analysis of late relapse in Hodgkin lymphoma.
Pinczés L; Miltényi Z; Illés Á
J Cancer Res Clin Oncol; 2018 May; 144(5):935-943. PubMed ID: 29468437
[TBL] [Abstract][Full Text] [Related]
40. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
